Neurocrine publication highlights need for integrated hyperphagia care in Prader-Willi syndrome
NBIX•Neurocrine Biosciences announced that expert perspectives on managing hyperphagia in Prader-Willi syndrome were published in Orphanet Journal of Rare Diseases. The experts described VYKAT XR as an important complement to behavioral and environmental support.
1. Expert perspectives published
Neurocrine Biosciences announced the publication of expert perspectives on managing hyperphagia in Prader-Willi syndrome in Orphanet Journal of Rare Diseases. The experts identified VYKAT XR, described as the first FDA-approved treatment for hyperphagia in PWS, as an important complement to behavioral and environmental support.
2. Multidisciplinary care
The publication supports multidisciplinary care throughout patients’ lives and broader assessments to capture symptoms that structured environments may mask.
